Today: 19 April 2026
SoundHound AI Stock Back in Focus After Vanguard Stops Reporting 5%-Plus Stake

SoundHound AI Stock Back in Focus After Vanguard Stops Reporting 5%-Plus Stake

NEW YORK, March 29, 2026, 12:11 EDT

  • Vanguard’s newest ownership filing indicates the parent had zero SoundHound shares as of March 13, following an internal realignment. The previous amendment showed it held 43.46 million shares, amounting to 11.58% of the class.
  • SoundHound ended Friday at $5.90, down 2.6%, despite pushing forward with fresh partnerships in enterprise and retail.
  • SoundHound AI posted 2025 revenue of $168.9 million, nearly doubling from a year earlier, and issued a 2026 outlook in the range of $225 million to $260 million.

Vanguard disclosed late Friday it’s dropped below the 5% ownership mark in SoundHound AI, following an internal shakeup. That takes the big institutional investor off the roster of the conversational-AI firm’s major holders. SoundHound ended the session down 2.6% at $5.90.

Timing is crucial now for SoundHound. The company’s coming off another year in the red and a new CFO just stepped in. Its push to convert a series of enterprise and retail wins into reliable growth is under the microscope, with investors watching closely as it sticks to a 2026 revenue target.

Vanguard’s latest amended Schedule 13G shows the parent company held zero shares as of March 13, ticking the box for ownership of 5% or less. According to Vanguard, a January 12 internal realignment means certain subsidiaries or business units now report their stakes on their own. Back in the October 31 amendment, Vanguard listed 43.46 million shares—good for 11.58% of SoundHound’s stock.

SoundHound, known for its voice and conversational AI tools, targets a range of businesses. Lately, it’s putting weight behind “agentic AI” — tech aimed at complex, multi-step tasks that mostly run without much human help. The move signals a shift, as SoundHound stretches further from autos and into areas like customer support, retail, and IT. Reuters

This month, SoundHound linked up with ManpowerGroup’s Experis, which plans to resell the company’s conversational AI offerings to big organizations—healthcare gets the first shot. Peet’s Coffee is also rolling out the tech, putting voice-powered recipe lookup, troubleshooting and procedures in the hands of staff. “Enterprises were eager to move beyond experimentation,” said Chief Executive Keyvan Mohajer. Experis U.S. President Kye Mitchell pointed out that the real challenge lies in converting AI investments into “real business outcomes.” SoundHound AI

SoundHound on Thursday announced that Aragon Research has marked it as a leader in the 2026 agent-platforms report, a vendor ranking the company now highlights in its enterprise marketing. Still, Aragon’s release carried a disclaimer—it doesn’t endorse any vendor or product.

The company posted 2025 revenue of $168.9 million—a 99% jump over last year—and projected 2026 revenue in the $225 million to $260 million range. Cash stood at $248 million at the close of 2025, with zero debt on the books.

SoundHound’s expansion into enterprise software is putting it up against a wider field of AI competitors, on top of its established automotive foes. Cerence, according to Reuters profiles, is still concentrating on AI assistants inside connected cars. C3.ai, by contrast, markets enterprise-focused AI software to a range of sectors.

The road ahead isn’t straightforward. On March 18, SoundHound disclosed that CFO Nitesh Sharan plans to exit on April 3, with co-founder James Hom set to take over as interim CFO. Filings from this week also show CEO Keyvan Mohajer and other top execs sold shares on March 20—those sales were for tax withholding tied to vested stock awards. Back in February, the company’s earnings report flagged potential trouble spots: commercializing its products, keeping and winning customers, and covering costs from acquisitions could all weigh on results.

At this point, Vanguard’s filing seems to signal a change in how it reports its holdings, rather than a full-scale exit. Still, the stock finished Friday at $5.90, and the company has yet to prove that recent deals will generate solid, lasting cash flow. Investors aren’t likely to stop scrutinizing every new filing for clues.

Stock Market Today

  • Senator Mitch McConnell Earns $2.6M From Stock Market in April 2026
    April 19, 2026, 1:17 AM EDT. Senator Mitch McConnell earned an estimated $2.6 million from stock market activities last month, according to Quiver Quantitative's live net worth estimates. As of April 19, 2026, McConnell's net worth stands around $67.1 million, ranking him 24th richest in Congress. He holds approximately $47.9 million in publicly traded assets. Recent trade highlights include the sale and purchase of stocks with varying performance, such as a 127% rise in VMC and a 94% drop in LAZR. McConnell's latest fundraising reports show $7.3 million cash on hand and no new fundraising in Q1 2026. Quiver Quantitative provides ongoing tracking of his financial activities and legislative proposals.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 19.04.2026

19 April 2026
LIVEMarkets rolling coverageStarted: April 19, 2026, 12:00 AM EDTUpdated: April 19, 2026, 1:25 AM EDT Senator Mitch McConnell Earns $2.6M From Stock Market in April 2026 April 19, 2026, 1:17 AM EDT. Senator Mitch McConnell earned an estimated $2.6 million from stock market activities last month, according to Quiver Quantitative's live net worth estimates. As of April 19, 2026, McConnell's net worth stands around $67.1 million, ranking him 24th richest in Congress. He holds approximately $47.9 million in publicly traded assets. Recent trade highlights include the sale and purchase of stocks with varying performance, such as a 127% rise in
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Grab Holdings’ $600 Million Foodpanda Taiwan Deal Faces Fresh Scrutiny Over Uber Stake
Previous Story

Grab Holdings’ $600 Million Foodpanda Taiwan Deal Faces Fresh Scrutiny Over Uber Stake

US Stock Market Week Ahead: Dow Correction, Good Friday Jobs Report and Oil Jolt Put Wall Street on Edge
Next Story

US Stock Market Week Ahead: Dow Correction, Good Friday Jobs Report and Oil Jolt Put Wall Street on Edge

Go toTop